To identify the origin of the deleterious mutations of FGFR1 and MED12 in cfDNA, the DNA from the PMT tissues and normal tissues of the three TIO patients in the validation cohort was sequenced using the NGS panel targeting 422 cancer‐relevant genes (Table S1). This evidence concerns the gene MED12 and cancer.